For the latest ecancer COVID-19 resources, click on this link

Breast

Prostate & urology

Lung & pleura

Colorectal & gastro

Melanoma & skin

Head & neck

Ovary & gynaecology

+ -

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

ASCO 2020

27 May - 1 Jun 2020

Chicago, United States of America

The future of PARP inhibitors in prostate cancer

Dr Elena Castro - Spanish National Cancer Research Center, Madrid, Spain

The future of PARP inhibitors in prostate cancer ( Dr Elena Castro - Spanish National Cancer Research Center, Madrid, Spain )

COMBI-AD trial: Adjuvant dabrafenib plus trametinib in patients with resected st...

Prof Axel Hauschild - University Hospital, Schleswig-Holstein, Germany

COMBI-AD trial: Adjuvant dabrafenib plus trametinib in patients with resected stage III BRAF V600–mutant melanoma ( Prof Axel Hauschild - University Hospital, Schleswig-Holstein, Germany )

IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial c...

Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA

IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial cancer ( Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA )

Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC

Prof Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany

Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC ( Prof Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany )

ASCO 2020: Updates in non-metastatic castration-resistant prostate cancer

Prof Boris Hadaschik - University of Duisburg-Essen, Essen, Germany

ASCO 2020: Updates in non-metastatic castration-resistant prostate cancer ( Prof Boris Hadaschik - University of Duisburg-Essen, Essen, Germany )

MINDACT long-term results: 70-gene signature MammaPrint to guide adjuvant chemot...

Dr Fatima Cardoso - Champalimaud Clinical Center, Lisbon, Portugal

MINDACT long-term results: 70-gene signature MammaPrint to guide adjuvant chemotherapy use in breast cancer ( Dr Fatima Cardoso - Champalimaud Clinical Center, Lisbon, Portugal )

Early safety from a trial of talimogene laherparepvec (T-VEC) injected into live...

Prof J. Randy Hecht - UCLA Jonsson Comprehensive Cancer Center, Santa Monica, US...

Early safety from a trial of talimogene laherparepvec (T-VEC) injected into liver tumours plus pembrolizumab ( Prof J. Randy Hecht - UCLA Jonsson Comprehensive Cancer Center, Santa Monica, USA )

CITYSCAPE: Tiragolumab plus atezolizumab for non-small cell lung cancer

Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA

CITYSCAPE: Tiragolumab plus atezolizumab for non-small cell lung cancer ( Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA )

Phase II data from the KarMMa trial for relapsed/refractory multiple myeloma

Dr Nikhil Munshi - Dana Farber Cancer Institute, Boston, USA

$Phase II data from the KarMMa trial for relapsed/refractory multiple myeloma ( Dr Nikhil Munshi - Dana Farber Cancer Institute, Boston, USA )$

Pembrolizumab vs brentuximab vedotin in relapsed or refractory classic Hodgkin l...

Dr John Kuruvilla - Princess Margaret Cancer Centre, Toronto, Canada

$Pembrolizumab vs brentuximab vedotin in relapsed or refractory classic Hodgkin lymphoma ( Dr John Kuruvilla - Princess Margaret Cancer Centre, Toronto, Canada )$

FGFR inhibitors in bladder cancer: Testing, screening and highlights from ASCO 2...

Prof Robert Huddart and Dr Ignacio Durán

FGFR inhibitors in bladder cancer: Testing, screening and highlights from ASCO 2020 ( Prof Robert Huddart and Dr Ignacio Durán )

Perioperative chemotherapy with mFOLFIRINOX vs gemcitabine/nab-paclitaxel for re...

Prof Davendra Sohal - University of Cincinnati, Cincinnati, USA

Perioperative chemotherapy with mFOLFIRINOX vs gemcitabine/nab-paclitaxel for resectable pancreatic ductal adenocarcinoma ( Prof Davendra Sohal - University of Cincinnati, Cincinnati, USA )

High-dose twice daily thoracic radiotherapy in limited disease small-cell lung c...

Prof Bjørn Henning Grønberg - Trondheim University Hospital, Trondheim, Norway

High-dose twice daily thoracic radiotherapy in limited disease small-cell lung cancer ( Prof Bjørn Henning Grønberg - Trondheim University Hospital, Trondheim, Norway )

ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for ...

Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia

ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for patients with Waldenström macroglobulinemia ( Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia )

Background of the KEYLYNK-007 trial for advanced solid tumours

Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA

Background of the KEYLYNK-007 trial for advanced solid tumours ( Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA )

CTC count as a prognostic marker for androgen deprivation plus orteronel or bica...

Dr Amir Goldkorn - Keck School of Medicine of USC, Los Angeles, USA

CTC count as a prognostic marker for androgen deprivation plus orteronel or bicalutamide in mCSPC ( Dr Amir Goldkorn - Keck School of Medicine of USC, Los Angeles, USA )

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in...

Prof Thierry Conroy - Institute Cancer De Lorraine, Nancy, France

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer ( Prof Thierry Conroy - Institute Cancer De Lorraine, Nancy, France )

AGO DESKTOP III/ENGOT-ov20: Impact of secondary cytoreductive surgery in recurre...

Prof Andreas du Bois - Kliniken Essen Mitte, Essen, Germany

AGO DESKTOP III/ENGOT-ov20: Impact of secondary cytoreductive surgery in recurrent ovarian cancer ( Prof Andreas du Bois - Kliniken Essen Mitte, Essen, Germany )

Three versus six months of adjuvant oxaliplatin and fluoropyrimidine-based thera...

Prof Alberto Sobrero - Ospedale Policlinico San Martino, Genova, Italy

Three versus six months of adjuvant oxaliplatin and fluoropyrimidine-based therapy for patients with stage III colon cancer ( Prof Alberto Sobrero - Ospedale Policlinico San Martino, Genova, Italy )

Checkpoint inhibitors for the treatment of advanced hepatocellular carcinoma

Dr Katie Kelley - University of California San Francisco, San Francisco, USA

Checkpoint inhibitors for the treatment of advanced hepatocellular carcinoma ( Dr Katie Kelley - University of California San Francisco, San Francisco, USA )

Reducing damage to swallowing muscles during radiotherapy for head and neck canc...

Prof Christopher Nutting - The Royal Marsden NHS Foundation Trust, London, UK

Reducing damage to swallowing muscles during radiotherapy for head and neck cancers ( Prof Christopher Nutting - The Royal Marsden NHS Foundation Trust, London, UK )

Updated results from KEYNOTE-426 for metastatic kidney cancer

Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA

Updated results from KEYNOTE-426 for metastatic kidney cancer ( Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA )

HCRN GU16-260: Nivolumab and salvage nivolumab ipilimumab in treatment-naïve p...

Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA

HCRN GU16-260: Nivolumab and salvage nivolumab ipilimumab in treatment-naïve patients with advanced renal cell carcinoma ( Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA )

Comment: JAVELIN-100 for metastatic urothelial cancer

Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA

Comment: JAVELIN-100 for metastatic urothelial cancer ( Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA )

3-weekly cisplatin or weekly cisplatin for squamous cell carcinoma of head and n...

Dr Naomi Kiyota - Kobe University, Kobe, Japan

3-weekly cisplatin or weekly cisplatin for squamous cell carcinoma of head and neck ( Dr Naomi Kiyota - Kobe University, Kobe, Japan )

Osimertinib plus gefitinib for treatment of EGFR-mutated non-small cell lung can...

Dr Julia Rotow - Dana Farber Cancer Institute, Boston, USA

Osimertinib plus gefitinib for treatment of EGFR-mutated non-small cell lung cancer ( Dr Julia Rotow - Dana Farber Cancer Institute, Boston, USA )

METex14 SAs (MET exon 14 skipping alterations) in non-small cell lung cancer

Prof Mark Awad - Dana Farber Cancer Institute, Boston, USA

METex14 SAs (MET exon 14 skipping alterations) in non-small cell lung cancer ( Prof Mark Awad - Dana Farber Cancer Institute, Boston, USA )

PARP inhibitors in prostate cancer: Choices of tests and how to test?

Dr Kim Chi and Dr Alexander Wyatt

PARP inhibitors in prostate cancer: Choices of tests and how to test? ( Dr Kim Chi and Dr Alexander Wyatt )

ASCO 2020: Breast cancer roundup

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

ASCO 2020: Breast cancer roundup ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

FORTE trial: Minimal residual disease evaluation in newly diagnosed multiple mye...

Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy

FORTE trial: Minimal residual disease evaluation in newly diagnosed multiple myeloma ( Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy )

The PANDA study: Combining panitumumab with FOLFOX or 5FU in elderly patients wi...

Dr Sara Lonardi - Istituto Oncologico Veneto, Padua, Italy

The PANDA study: Combining panitumumab with FOLFOX or 5FU in elderly patients with RAS-BRAF WT metastatic colorectal cancer ( Dr Sara Lonardi - Istituto Oncologico Veneto, Padua, Italy )

Comparing pevonedistat plus azacitidine versus azacitidine alone in patients wit...

Prof Lionel Ades - Hôpital Saint-Louis, Paris, France

Comparing pevonedistat plus azacitidine versus azacitidine alone in patients with higher-risk MDS/CMML or low-blast AML ( Prof Lionel Ades - Hôpital Saint-Louis, Paris, France )

ASCO 2020 prostate cancer highlights

Prof Karim Fizazi, Prof Axel Merseburger, Dr Kim Chi and Prof Amit Bahl

ASCO 2020 prostate cancer highlights ( Prof Karim Fizazi, Prof Axel Merseburger, Dr Kim Chi and Prof Amit Bahl )

Perioperative novel systemic immunotherapy-based approaches in urinary cancers

Dr Shilpa Gupta - Cleveland Clinic, Cleveland, USA

Perioperative novel systemic immunotherapy-based approaches in urinary cancers ( Dr Shilpa Gupta - Cleveland Clinic, Cleveland, USA )

ASCO 2020: Updates in renal cancer

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

ASCO 2020: Updates in renal cancer ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

TROPHIMMUN: Avelumab for gestational trophoblastic tumours resistant to monochem...

Prof Benoit You - Hospices Civils de Lyon, Lyon, France

TROPHIMMUN: Avelumab for gestational trophoblastic tumours resistant to monochemotherapy ( Prof Benoit You - Hospices Civils de Lyon, Lyon, France )

KEYNOTE-177 results: Pembrolizumab versus chemotherapy for patients with MSI-H/d...

Prof Thierry Andre - Sorbonne University and Saint-Antoine Hospital, Paris, Fran...

KEYNOTE-177 results: Pembrolizumab versus chemotherapy for patients with MSI-H/dMMR colorectal cancer ( Prof Thierry Andre - Sorbonne University and Saint-Antoine Hospital, Paris, France )

Highlights from ASCO 2020

Dr Bishal Gyawali - Queen's University, Kingston, Canada

Highlights from ASCO 2020 ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

PARP inhibitors in prostate cancer: Guidelines, who to test and the patient path...

Dr Neal Shore and Dr Elena Castro

PARP inhibitors in prostate cancer: Guidelines, who to test and the patient pathway ( Dr Neal Shore and Dr Elena Castro )

New emerging treatment options and targeted therapies for bladder cancer

Dr Arlene Siefker-Radtke and Dr Yohann Loriot

New emerging treatment options and targeted therapies for bladder cancer ( Dr Arlene Siefker-Radtke and Dr Yohann Loriot )

Timing of response to venetoclax combination treatment in older patients with ac...

Dr Brian Jonas - University of California Davis Comprehensive Cancer Center, Sac...

Timing of response to venetoclax combination treatment in older patients with acute myeloid leukaemia ( Dr Brian Jonas - University of California Davis Comprehensive Cancer Center, Sacramento, USA )

CheckMate 227 three-year update: Nivolumab plus ipilimumab versus chemo as first...

Prof Suresh Ramalingam - Winship Cancer Institute of Emory University, Atlanta, ...

CheckMate 227 three-year update: Nivolumab plus ipilimumab versus chemo as first-line treatment for advanced NSCLC ( Prof Suresh Ramalingam - Winship Cancer Institute of Emory University, Atlanta, USA )

ASCO 2020: Latest developments in EGFR-mutated non-small cell lung cancer

Prof Benjamin Besse and Dr Alex Spira

ASCO 2020: Latest developments in EGFR-mutated non-small cell lung cancer ( Prof Benjamin Besse and Dr Alex Spira )

Venetoclax with bortezomib and dexamethasone in relapsed/refractory multiple mye...

Dr Shaji Kumar - Mayo Clinic, Rochester, USA

$Venetoclax with bortezomib and dexamethasone in relapsed/refractory multiple myeloma ( Dr Shaji Kumar - Mayo Clinic, Rochester, USA )$

KRd vs VRd for initial therapy of newly diagnosed multiple myeloma

Dr Shaji Kumar - Mayo Clinic, Rochester, USA

KRd vs VRd for initial therapy of newly diagnosed multiple myeloma ( Dr Shaji Kumar - Mayo Clinic, Rochester, USA )

Teclistamab for patients with heavily pretreated relapsed or refractory multiple...

Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA

$Teclistamab for patients with heavily pretreated relapsed or refractory multiple myeloma ( Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA )$

E2108: Systemic therapy plus early local therapy versus systemic therapy alone i...

Dr Seema Ahsan Khan - Northwestern Memorial Hospital, Chicago, USA

E2108: Systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer ( Dr Seema Ahsan Khan - Northwestern Memorial Hospital, Chicago, USA )

KEYNOTE-604: Pembrolizumab plus etoposide and platinum as a first-line therapy f...

Dr Charles Rudin - Memorial Sloan Kettering Cancer Center, New York City, USA

KEYNOTE-604: Pembrolizumab plus etoposide and platinum as a first-line therapy for extensive-stage small-cell lung cancer ( Dr Charles Rudin - Memorial Sloan Kettering Cancer Center, New York City, USA )

Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19 and ...

Dr Dimpy Shah - Mays Cancer Center at UT Health San Antonio MD Anderson, San Ant...

Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19 and Cancer Consortium (CCC19) ( Dr Dimpy Shah - Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, USA )

Cumulative incidence of financial hardship in metastatic colorectal cancer patie...

Dr Veena Shankaran - Fred Hutchinson Cancer Research Center, Seattle, USA

Cumulative incidence of financial hardship in metastatic colorectal cancer patients: Primary endpoint results for SWOG S1417CD ( Dr Veena Shankaran - Fred Hutchinson Cancer Research Center, Seattle, USA )

Denosumab in multiple myeloma patients with renal insufficiency

Dr Elizabeth O'Donnell - Massachusetts General Hospital, Boston, USA

Denosumab in multiple myeloma patients with renal insufficiency ( Dr Elizabeth O'Donnell - Massachusetts General Hospital, Boston, USA )

Association of BRCA alterations with response to PARP inhibitors in metastatic c...

Dr Emmanuel Antonarakis - John Hopkins Sidney Kimmel Comprehensive Cancer Center...

Association of BRCA alterations with response to PARP inhibitors in metastatic castration-resistant prostate cancer ( Dr Emmanuel Antonarakis - John Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA )

LuPSMA vs cabazitaxel in metastatic castration-resistant prostate cancer progres...

Prof Michael Hofman - Peter MacCallum Cancer Centre, Melbourne, Australia

LuPSMA vs cabazitaxel in metastatic castration-resistant prostate cancer progressing after docetaxel ( Prof Michael Hofman - Peter MacCallum Cancer Centre, Melbourne, Australia )

The paediatric precision oncology study INFORM: Clinical outcome and benefit for...

Dr Cornelis van Tilburg - Hopp Children's Cancer Center Heidelberg, Heidelberg, ...

The paediatric precision oncology study INFORM: Clinical outcome and benefit for molecular subgroups ( Dr Cornelis van Tilburg - Hopp Children's Cancer Center Heidelberg, Heidelberg, Germany )

Maintenance avelumab plus best supportive care (BSC) versus BSC alone after chem...

Prof Thomas Powles - Barts Cancer Institute, London, UK

Maintenance avelumab plus best supportive care (BSC) versus BSC alone after chemotherapy in advanced urothelial carcinoma ( Prof Thomas Powles - Barts Cancer Institute, London, UK )

Brigatinib for NSCLC, latest research and overcoming complications

Dr Ross Camidge - University of Colorado Cancer Center, Aurora, USA

Brigatinib for NSCLC, latest research and overcoming complications ( Dr Ross Camidge - University of Colorado Cancer Center, Aurora, USA )

Sym015 shows superior specificity compared to TKIs for NSCLC

Dr Ross Camidge - University of Colorado Cancer Center, Aurora, USA

Sym015 shows superior specificity compared to TKIs for NSCLC ( Dr Ross Camidge - University of Colorado Cancer Center, Aurora, USA )

CARTITUDE-1: JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell th...

Dr Jesus Berdeja - Sarah Cannon Research Institute, Nashville, USA

CARTITUDE-1: JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy for r/r multiple myeloma ( Dr Jesus Berdeja - Sarah Cannon Research Institute, Nashville, USA )

Update from KAITLIN for high-risk HER2-positive early breast cancer

Dr Julie Gralow - University of Washington School of Medicine, Seattle, USA

Update from KAITLIN for high-risk HER2-positive early breast cancer ( Dr Julie Gralow - University of Washington School of Medicine, Seattle, USA )

Cisplatin plus/minus veliparib in metastatic TNBC and/or germline BRCA-associate...

Dr Julie Gralow - University of Washington School of Medicine, Seattle, USA

Cisplatin plus/minus veliparib in metastatic TNBC and/or germline BRCA-associated breast cancer ( Dr Julie Gralow - University of Washington School of Medicine, Seattle, USA )

Better genetic diagnostics in Ugandan breast cancer patients

Dr Julie Gralow - University of Washington School of Medicine, Seattle, USA

Better genetic diagnostics in Ugandan breast cancer patients ( Dr Julie Gralow - University of Washington School of Medicine, Seattle, USA )

ADAURA results: Adjuvant osimertinib for EGFRm non-small cell lung cancer

Prof Roy Herbst - Yale Cancer Center, New Haven, USA

ADAURA results: Adjuvant osimertinib for EGFRm non-small cell lung cancer ( Prof Roy Herbst - Yale Cancer Center, New Haven, USA )

Pembrolizumab plus chemotherapy for patients with metastatic triple-negative bre...

Dr Javier Cortés - IOB Institute of Oncology, Madrid and Barcelona, Spain

Pembrolizumab plus chemotherapy for patients with metastatic triple-negative breast cancer ( Dr Javier Cortés - IOB Institute of Oncology, Madrid and Barcelona, Spain )

More from ecancer